{"name":"PTC Therapeutics","slug":"ptc-therapeutics","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":6,"colorKey":"oncology","drugs":[{"name":"PTC518","genericName":"PTC518","slug":"ptc518","indication":"Other","status":"phase_2"},{"name":"Deflazacort and rifampin","genericName":"Deflazacort and rifampin","slug":"deflazacort-and-rifampin","indication":"Other","status":"phase_1"},{"name":"Translarna","genericName":"ATALUREN","slug":"ataluren","indication":"Duchenne muscular dystrophy","status":"marketed"},{"name":"CNSA-001","genericName":"CNSA-001","slug":"cnsa-001","indication":"Spinal Muscular Atrophy","status":"phase_2"},{"name":"PTC124","genericName":"PTC124","slug":"ptc124","indication":"Other","status":"phase_2"},{"name":"Upstaza","genericName":"ELADOCAGENE EXUPARVOVEC","slug":"eladocagene-exuparvovec","indication":"Deficiency of aromatic-L-amino-acid decarboxylase","status":"marketed"}]},{"name":"Rare Disease","slug":"rare-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Ataluren (PTC124®)","genericName":"Ataluren (PTC124®)","slug":"ataluren-ptc124","indication":"Duchenne muscular dystrophy (DMD) with nonsense mutations","status":"phase_3"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"PTC923","genericName":"PTC923","slug":"ptc923","indication":"Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE)","status":"phase_3"}]}],"pipeline":[{"name":"PTC518","genericName":"PTC518","slug":"ptc518","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Deflazacort and rifampin","genericName":"Deflazacort and rifampin","slug":"deflazacort-and-rifampin","phase":"phase_1","mechanism":"Deflazacort is a corticosteroid with anti-inflammatory effects; rifampin induces CYP3A4 enzymes that metabolize deflazacort.","indications":[],"catalyst":""},{"name":"Translarna","genericName":"ATALUREN","slug":"ataluren","phase":"marketed","mechanism":"Flavin reductase (NADPH)","indications":["Duchenne muscular dystrophy"],"catalyst":""},{"name":"Ataluren (PTC124®)","genericName":"Ataluren (PTC124®)","slug":"ataluren-ptc124","phase":"phase_3","mechanism":"Ataluren allows ribosomes to read through premature stop codons (nonsense mutations) and produce full-length, functional proteins.","indications":["Duchenne muscular dystrophy (DMD) with nonsense mutations","Cystic fibrosis with nonsense mutations","Hemophilia B Leyden"],"catalyst":""},{"name":"CNSA-001","genericName":"CNSA-001","slug":"cnsa-001","phase":"phase_2","mechanism":"CNSA-001 is a small molecule that targets the underlying cause of a specific disease.","indications":["Spinal Muscular Atrophy"],"catalyst":""},{"name":"PTC124","genericName":"PTC124","slug":"ptc124","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"PTC923","genericName":"PTC923","slug":"ptc923","phase":"phase_3","mechanism":"PTC923 is a small-molecule inhibitor of pyruvate dehydrogenase kinase (PDK) that restores pyruvate dehydrogenase (PDH) activity to improve mitochondrial energy metabolism.","indications":["Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE)","Other mitochondrial or metabolic disorders"],"catalyst":""},{"name":"Upstaza","genericName":"ELADOCAGENE EXUPARVOVEC","slug":"eladocagene-exuparvovec","phase":"marketed","mechanism":"Upstaza works by replacing the deficient enzyme aromatic-L-amino-acid decarboxylase.","indications":["Deficiency of aromatic-L-amino-acid decarboxylase"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxPOTFQX2hqWC1QX0tKcVhNRjcxY1hrTmZ3X0d1NWgta0Z5c3FNNzdVdUU4NzFQLXpyWGxuUHVBY3JGMFNPYkttaGx1cm45V3RQa0FXbEdGU3QxWEJhTFBSSUQ5M1Vjb2UwMlJPNXIxR2RwYUJ3Y3VtM2dCS2RTV1B4M0llZnRhZVhMZGhjczBaOUE0Z19LR1pOMA?oc=5","date":"2026-02-16","type":"regulatory","source":"Pharmaceutical Technology","summary":"PTC pulls Translarna NDA after unfavourable FDA feedback - Pharmaceutical Technology","headline":"PTC pulls Translarna NDA after unfavourable FDA feedback","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxOb2RvWi03b2dCLVdPdlhoNWU5LXVjb21jb3dXOEUtZHRoczZ5emQ0cXc1MUUyZUJwQ2F4UzQ1TzdpM0xLWlBXaDhFVTB3VXJqc2hNc05EX0ZHMUJWMU9KOGtCemFWcVBwQk82b0daTkItUV8xU1FHZF9aMVFpaEk2TzgtOXdhVm1pMGRkNEYyZ0gyUUdHcjFoYXNka2k1RzloWVE?oc=5","date":"2026-02-13","type":"regulatory","source":"fiercepharma.com","summary":"PTC shuts down FDA approval bid for troubled Duchenne med Translarna - fiercepharma.com","headline":"PTC shuts down FDA approval bid for troubled Duchenne med Translarna","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMif0FVX3lxTE9BTnI2REFTQi1hTjlZUEgtWDlwczc2M1hFbm1zUTNwZW9ISGplV3RWUUQ3eXJOc3hCS2UyWElnRnpNRGlyRTJYY2ZqcXl6T1V5ajRMejhaSlRvNmNsSFN0eVZmbjg4VE9EbUZ4R0pTOEp1WEtlSG96b254T09YY0U?oc=5","date":"2026-02-13","type":"regulatory","source":"pharmaphorum","summary":"PTC pulls file for Duchenne therapy on FDA feedback - pharmaphorum","headline":"PTC pulls file for Duchenne therapy on FDA feedback","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxNd1J6T25LMVJIeERaQm5ZMWdTeVNweE5DUFJmXzB1dTlwaVJMSkt4Mk9xemZPVnFuYWQ5SzBQdmhmVEpTcmxMQUhOQk9mSG5uMUxLR2ZpNm5jZXV1SjRhRV9MeXFKM28wT1FVSWhkYUQ5NmllLXNNWmRtYXFHcElSUEtMRUluOVdVb0NfSFhn?oc=5","date":"2026-02-13","type":"pipeline","source":"The Pharma Letter","summary":"PTC Therapeutics withdraws Translarna NDA - The Pharma Letter","headline":"PTC Therapeutics withdraws Translarna NDA","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxNdjNLTGFLZF9mU3Z1VzItWUQ1YlJIX2hLWnBfNnBDbWlNYjBDWk4tVV81MU9ZWUhYSmUtRmI4ak1sNjU0MkFSVi11NWFjcHlXaS0zeFBFTmlmYTJjSG9ORktjZkx6NGw2NHptNW5jTmw0aVhIbVFkMjRtVjlIQnBMamdLd3RSaDJPZ1ZKRjdWcGhwMmNpX0xNSXRmc3MtV0V3Mzl2emNqaUdyUQ?oc=5","date":"2026-02-13","type":"regulatory","source":"MedCity News","summary":"PTC Therapeutics Ends Bid to Seek FDA Approval for Rare Muscle Disease Drug - MedCity News","headline":"PTC Therapeutics Ends Bid to Seek FDA Approval for Rare Muscle Disease Drug","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE9DMllXeVRuNTN2dTZhcFZRa0FNZGdtaTd5eHp1M29TcllTZkxwd1NYOWlyVmd6aFJLbEdFY3M5LXkxQzdreFBMWDNUNjJZV1NWZS04?oc=5","date":"2026-02-12","type":"regulatory","source":"FirstWord Pharma","summary":"Final US chapter for PTC's DMD therapy Translarna as FDA bar proves too high - FirstWord Pharma","headline":"Final US chapter for PTC's DMD therapy Translarna as FDA bar proves too high","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxOY1VtTjBOT3lrNDE0U3IxNF9yUVc2dEYzdFBTSTI0ZkVaOEVqRGJJcE9xYmNTMnR0U1MwZDBsbXNfbzN6Y2FPdFhiRmo0UUh0RUVRU0JpRF9WTHVrZjVRT3haS1Q0Yk04ZXliY0dZMG0wN0FCQm1oREhTcXRxal9EdDNYME5XWUMySE95M3F5bmZieWtDZ25TTWdjQk9XVDd2dXprMFNUaEp5UQ?oc=5","date":"2025-09-02","type":"pipeline","source":"Contract Pharma","summary":"RareMed Solutions Expands Relationship with PTC Therapeutics - Contract Pharma","headline":"RareMed Solutions Expands Relationship with PTC Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxNb1l4ZFByYlkxbWZPd2dnZ1YyaVVRZ3hyU2ZjWW5ZLVE4T25FNnFRdTJkSnBubjR3alFYRFJQS2dOelAwUWdjSnZzYXJ1ekV0Y1V5WU42M1hmVkhIZGlRRG9uU2o4R0cwdDFZR3hXZ3RzOXZQaXF6N1RTU3g3a1JqLW92Yw?oc=5","date":"2025-08-29","type":"regulatory","source":"Yahoo Finance","summary":"PTC Therapeutics, Inc. (PTCT) Faces FDA Setback on Vatiquinone for Friedreich’s Ataxia - Yahoo Finance","headline":"PTC Therapeutics, Inc. (PTCT) Faces FDA Setback on Vatiquinone for Friedreich’s Ataxia","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxOLU1TYkxUQ3o3Rmpfd1Z5bHJ2SDFMc0lZcUlNbHNiVHV6VlBVQ2FzS2tnYUgybjFxaXc0M05maEVORUFPOEhwRV8yWkFOYmNuZmNjUkhxR2pldGwxanNLTXRmTWVuT3QtZnpEZG55OEFZanhDdTg3LVZMY0psdV9Kd1BBOFJ2Q1F2QTVHNFBqRkh4alpGSHhZLUcwM0ZUOXRxREdjTHUtRE5tZGNVaFV2R2lna0xqTXZ3VC1uSQ?oc=5","date":"2025-08-19","type":"pipeline","source":"Mintz","summary":"Mintz Advises Former Shareholders of Censa Pharmaceuticals in the Sale of its Earnout Royalties Rights back to PTC Therapeutics - Mintz","headline":"Mintz Advises Former Shareholders of Censa Pharmaceuticals in the Sale of its Earnout Royalties Rights back to PTC Thera","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxOek1NVEJyLTYtTGwzcHlZUzRyUWF6eUtIclc5Zl9vQ1dnUjNvODVrb0xVSmxLbjRZRXB6bklCRlpoOXRCTExIVlU2d3dFcTJMV0xiUzNZeWluaGpab1BjYy12YUFuNjZPeXktTm1jNi1VUmNjQ2xFX3pYeGZVcE5UQ2NfYThRTDBoS2JqNUM4ODFhNmRsOEtSaU1ZdnY?oc=5","date":"2025-08-19","type":"regulatory","source":"Fierce Biotech","summary":"FDA rejection derails PTC Therapeutics' rare disease hopeful - Fierce Biotech","headline":"FDA rejection derails PTC Therapeutics' rare disease hopeful","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxNSUtUbkZqb3B3REhqZjVHR3cwQm9Ka2kzTUxBSURIUWlFTHYtSVJCZHcyQUpKbGxldV9aVXN4YXh0QWpIc0NsX3NQSWkxaThrOXozMzhJbnBmYkczN2JWOTBIT0ltT1BMbkxnY2NiVU1Ca1owY0FWQVAyeUJDVWRaZGdCMlUzNktJLV96c0xZNDA5c0xPdHJ3ZVJIVk5hUzQ4Xzl5OTdPNGdfUjR5clZVYkpRVG41aGhhZWVhclZBTUdBVms?oc=5","date":"2025-07-29","type":"regulatory","source":"Sahm","summary":"Sephience Gets FDA Approval, Now A Key Revenue Driver For PTC Therapeutics - Sahm","headline":"Sephience Gets FDA Approval, Now A Key Revenue Driver For PTC Therapeutics","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxNaFRRZ2pfRDNDcVdHSjZuVDVaYkRNQVg4VDRvQnZ0bEN0aHdlbENCSW9Vdm9uLWRPcDVVdVl5RGdxMzRoUUhORXBvanVlXzdoMi12S1VtM1MwUXQwbUQ0Y0w4WTJDZTF4eG5QZzBCRlVGeUZQci0wMjlDU09QdFFwVl84WFkwdjdlQjR0b1Y2NXR6bUVQSl9raGstRnNaMlNMdm4xaW9EMk5fOWNpcDc2MFVXOHR3WFFuMXMwZ2IwZjgwSmQ4amc4?oc=5","date":"2025-07-28","type":"regulatory","source":"Reuters","summary":"US FDA approves PTC Therapeutics' metabolic disorder drug - Reuters","headline":"US FDA approves PTC Therapeutics' metabolic disorder drug","sentiment":"positive"}],"patents":[],"drugCount":8,"phaseCounts":{"phase_2":3,"phase_1":1,"marketed":2,"phase_3":2},"enrichmentLevel":0,"visitCount":5,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}